Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 59 results for neuropathic pain

  1. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis, including where fertility is a priority. It aims to raise awareness of endometriosis symptoms, and to provide clear advice on referral, diagnosis and the range of treatments available.

    NICE guideline
    Last updated
    11 November 2024
    View recommendations

    Sections for NG73

  2. Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain?

    Question Does early intervention to treat neuropathic pain reduce the likelihood of chronic pain? Any explanatory notes(if...

    Research recommendation
    Published
    26 October 2020

  3. Is there a potential for dependence associated with pharmacological agents for neuropathic pain?

    potential for dependence associated with pharmacological agents for neuropathic pain? Any explanatory notes(if applicable) There has...

    Research recommendation
    Published
    26 October 2020

  4. Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness...

    Research recommendation
    Published
    9 June 2015

  5. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

    NICE guideline
    Published
    7 April 2021
    View recommendations

    Sections for NG193

  6. How should the symptomatic treatment of neuropathic pain relate to its cause?

    CG173/7 Question How should the symptomatic treatment of neuropathic pain relate to its cause? Any explanatory notes(if applicable)

    Research recommendation
    Published
    26 October 2020

  7. What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    and quality of life in neuropathic pain? Any explanatory notes(if applicable) Pharmacological agents for neuropathic pain...

    Research recommendation
    Published
    26 October 2020

  8. What are the key factors, including additional care and support, that influence participation* and quality of life in people with neuropathic pain?

    support, that influence participation* and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) * The...

    Research recommendation
    Published
    26 October 2020

  9. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    pharmacological monotherapy compared with combination therapy for treating neuropathic pain? Any explanatory notes(if applicable) Why...

    Research recommendation
    Published
    26 October 2020

  10. Factors affecting participation and quality of life:- What are the key factors, including additional care and support, that influence participation and quality of life in people with neuropathic pain?

    support, that influence participation and quality of life in people with neuropathic pain? Any explanatory notes(if applicable) Why this...

    Research recommendation
    Published
    9 June 2015

  11. Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment predicted more reliably by underlying aetiology or by symptom characteristics?

    CG173/2 Question Relationship between symptoms, cause of neuropathic pain and its treatment:- Is response to pharmacological treatment...

    Research recommendation
    Published
    9 June 2015

  12. Impact of drug-related adverse effects on cost effectiveness and quality of life:- What is the impact of drug-related adverse effects on health economics and quality of life in neuropathic pain?

    of life in neuropathic pain? Any explanatory notes(if applicable) Why this is important:- Pharmacological agents for neuropathic...

    Research recommendation
    Published
    9 June 2015

  13. NICE encourages further research into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about selection criteria and long-term outcomes, with clear documentation of the indications for treatment.

    into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about...

    Research recommendation
    Published
    9 June 2015

  14. For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of cannabidiol (CBD), containing no, or traces of, delta-9-tetrahydrocannabinol (THC), as an add-on to standard treatment?

    For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of...

    Research recommendation
    Published
    10 February 2020

  15. Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)

    NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .

    Medtech innovation briefing
    Published
    30 August 2022